Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3904/kjim.2016.091 http://scihub22266oqcxt.onion/10.3904/kjim.2016.091 C4855108!4855108 !27048251     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27048251 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Korean+J+Intern+Med 2016 ; 31 (3 ): 444-56 Nephropedia Template TP {{tp|p=27048251 |t=2016. Functional dyspepsia: new insights into pathogenesis and therapy |pdf=|usr=}}{{27048251 }} gab.com Text Functional dyspepsia: new insights into pathogenesis and therapy JO: Korean J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=27048251 #FOAvip One in 10 people suffer from functional dyspepsia (FD), a clinical syndrome comprising chronic bothersome early satiety, or postprandial fullness, or epigastric pain or burning. Postprandial distress syndrome (PDS, comprising early satiety and/or postprandial fullness) and epigastric pain syndrome (EPS) are increasingly accepted as valid clinical entities, based on new insights into the pathophysiology and the results of clinical trials. Diagnosis is based on the clinical history, and exclusion of peptic ulcer and cancer by endoscopy. Evidence is accumulating FD and gastroesophageal ref lux disease are part of the same disease spectrum in a major subset. The causes of FD remain to be established, but accumulating data suggest infections and possibly food may play an important role in subsets. FD does not equate with no pathology; duodenal eosinophilia is now an accepted association, and Helicobacter pylori infection is considered to be causally linked to dyspepsia although only a minority will respond to eradication. In those with EPS, acid suppression therapy is a first line therapy; consider a H2 blocker even if proton pump inhibitor fails. In PDS, a prokinetic is preferred. Second line therapy includes administration of a tricyclic antidepressant in low doses, or mirtazapine, but not a selective serotonin reuptake inhibitor. Twit Text FOAVip Functional dyspepsia: new insights into pathogenesis and therapy ????Korean J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=27048251 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27048251 #FOAvip English Wikipedia <ref>{{Cite pmid|27048251 }}</ref> Functional dyspepsia: new insights into pathogenesis and therapy #MMPMID27048251 Talley NJ Korean J Intern Med 2016[May]; 31 (3 ): 444-56 PMID27048251 show ga One in 10 people suffer from functional dyspepsia (FD), a clinical syndrome comprising chronic bothersome early satiety, or postprandial fullness, or epigastric pain or burning. Postprandial distress syndrome (PDS, comprising early satiety and/or postprandial fullness) and epigastric pain syndrome (EPS) are increasingly accepted as valid clinical entities, based on new insights into the pathophysiology and the results of clinical trials. Diagnosis is based on the clinical history, and exclusion of peptic ulcer and cancer by endoscopy. Evidence is accumulating FD and gastroesophageal ref lux disease are part of the same disease spectrum in a major subset. The causes of FD remain to be established, but accumulating data suggest infections and possibly food may play an important role in subsets. FD does not equate with no pathology; duodenal eosinophilia is now an accepted association, and Helicobacter pylori infection is considered to be causally linked to dyspepsia although only a minority will respond to eradication. In those with EPS, acid suppression therapy is a first line therapy; consider a H2 blocker even if proton pump inhibitor fails. In PDS, a prokinetic is preferred. Second line therapy includes administration of a tricyclic antidepressant in low doses, or mirtazapine, but not a selective serotonin reuptake inhibitor. |Anti-Bacterial Agents/therapeutic use [MESH] |Antidepressive Agents, Tricyclic/therapeutic use [MESH] |Dyspepsia/diagnosis/*drug therapy/epidemiology/physiopathology [MESH] |Gastrointestinal Agents/*therapeutic use [MESH] |Genetic Predisposition to Disease [MESH] |Helicobacter Infections/drug therapy/epidemiology/microbiology [MESH] |Helicobacter pylori/drug effects [MESH] |Histamine H2 Antagonists/therapeutic use [MESH] |Humans [MESH] |Predictive Value of Tests [MESH] |Proton Pump Inhibitors/therapeutic use [MESH] |Risk Factors [MESH]Functional dyspepsia: new insights into pathogenesis and therapy (epmc).pdf DeepDyve Pubget Overpricing